As a proof of concept, activity assays with one of the candidates, a putative chitinase, showed that functional protein was obtained using the low-temperature optimized vector suite.
Early clinical trials of these agents have established the safety of the approach and showed proof-of-concept antitumor activity [52].
The first proof-of-concept trial established activity of the AR antagonist, bicalutamide, in patients with advanced AR+ triple-negative breast cancer.
The secondary objectives were to obtain immunological proof-of-concept of antitumor activity of V γ9V δ2 T-cells and to evaluate its clinical benefit.
Proof-of concept experimental results are provided.
As a proof of concept the activity of the two-catalyst system was gauged for the addition of cyanide to α,β-unsaturated imides which has been shown to follow a bimetallic mechanism.
The Phase II proof-of-concept study showed comparable activity between afatinib and cetuximab in R/M HNSCC patients following failure of platinum-based chemotherapy.
These studies provide proof-of-concept evidence that mGlu7 activity can be modulated by positive allosteric modulation, paving the way for future therapeutics development.
Although a proof-of-concept compound, the selective activity demonstrated by 1 suggests the potential for the bioreductive release of targeted therapies and demonstrates this approach as a promising strategy for the targeted application of cancer chemotherapeutics.
Testing of the pAuNPs at a proof-of-concept level demonstrated its higher electrocatalytical activity than other two structures towards oxygen reduction in both acidic and alkaline media.
Here we present a proof-of-concept immobilization approach that allows exoelectrogenic activity of cells on an electrode based on applying a layer of latex to hold bacteria on surfaces.
